Schisandrin A enhances the cytotoxicity of doxorubicin by the inhibition of nuclear factor-kappa B signaling in a doxorubicin-resistant human osteosarcoma cell line

Schisandrin A reversed chemoresistance in doxorubicin-induced MG-63 subline by inhibiting NF-kappaB-mediate expression of P-gp.